Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
3 papers
Researchers found that the main kratom alkaloid, mitragynine, is turned by liver enzymes into a much more active compound called 7-hydroxymitragynine (7‑OH). In lab tests and in mice, 7‑OH acts more strongly at the mu-opioid receptor and reaches brain levels that can explain most or all of the pain relief…
This page describes ibogaine as a plant-derived psychedelic that some researchers are studying for addiction, depression, and PTSD. It says ibogaine can cause strong hallucinations that start within hours and may last up to 24 hours. The page reports some studies and a 2022 review that suggest ibogaine may reduce…
Researchers reviewing ibogaine and its chemical relatives say these drugs point to a new way to treat substance use disorders by blocking a brain receptor called α3β4 nicotinic acetylcholine receptor (nAChR). Animal studies found ibogaine and some derivatives reduced self-use of drugs like morphine, cocaine, alcohol, and nicotine. But ibogaine…
